Definium Therapeutics
This foundational leadership role reports to the VP of Sales and owns the end-to-end strategy and execution of sales training and capability development for a novel CNS product. The position involves designing comprehensive training curricula, delivering high-impact learning experiences, and partnering with cross-functional teams to ensure scientific accuracy and compliance. Success in this role directly influences launch readiness, field force excellence, and long-term commercial performance.
Headquarters
New York, New York, United States
Company Size
1-10 employees
Founded
2019
Definium Therapeutics (formerly MindMed) is a clinical-stage biopharmaceutical company harnessing the therapeutic potential of psychedelic medicine to develop treatments for psychiatric conditions including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Its lead programs include DT120 ODT, a proprietary formulation of lysergide (LSD) D-tartrate, and DT402, the R-enantiomer of MDMA targeting core symptoms of autism spectrum disorder. The company is guided by precision science and evidence-based development to redefine mental healthcare.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Definium Therapeutics.
Associate Director, Market Access Strategy & Capability Development
Bristol Myers Squibb
Senior Instructional Designer, Sales & Product Training
C0000160857P
Senior Instructional Designer, Sales & Product Training
C0000160857P
Sales Training Manager
AstraZeneca
Associate Director, Field Medical Capability Development & Training
Bausch + Lomb
Senior Manager-Manufacturing Training & Capability Development
SC